Business
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered
About this update from Sana Biotechnology, Inc.
[{"type":"text","content":"SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA. Oral Presentations: Title:A Novel Technique to Detect Peripheral Blood CAR+ T Cells Using RNAscope In Situ Hybridization (ISH) in Non-Human Primates and MiceSummary:A novel cell-block method can be used to detect circulating CAR T cells in preclinical studies by evaluating the expression of Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) by Fluorescence in situ hybridization (FISH) in lieu of flow cytometry or PCR.Session:Pharmacology/Toxicology Studies: Bio DistributionSession Location:Petree Hall CSession Date/Time:Friday, May 19, 2023; 3:45 p.m. – 5:30 p.m. PTPresentation Time:5:00 p.m. – 5:15 p.m. PTAbstract Number:240 Title:Target Cell and Tissue Specificity of a Novel CD8-Targeted Fusosome for Direct In Vivo Delivery of CD19 or a CD20 CAR to CD8+ T CellsSummary:A panel of in vitro studies confirmed cell-specific transduction, CAR Expression, and target cell killing, supporting safe in vivo administration of Sana’s novel CD8-directed fusosomes for CAR T therapies.Session:Pharmacology/Toxicology Studies: In Vitro and In Vivo SafetySession Location:Petree Hall CSession Date/Time:Saturday, May 20, 2023; 8:00 a.m. – 9:45 a.m. PTPresentation Time:9:15 a.m. – 9:30 a.m. PTAbstract Number:317 Poster Presentations: Title:Advancements in Manufacturing of CD8-Targeted Fusosomes Enhance Transduction of Resting T Cells In Vitro and In VivoSummary: Process improvements were made to the manufacturing of Sana’s CD8 targeted fusosome for in vivo CAR T therapy, resulting in enhanced resting T cell transduction and in vitro and in vivo tumor killing.Session: Wednesday Poster SessionSession Date/Time:Wednesday, May 17, 2023; 12:00 p.m. PTAbstract Number:760 Title:Temsirolimus and IL-7 Treatment Synergistically Increase Primary Resting CD8+ T Cell Transduction with CD8-Targeted Fusosomes and Enhance CD19CAR ExpressionSummary:The use of IL-7 and Rapamycin analogs (Rapalogs) wit...